The MHRA has approved the reclassification of Nexium Control (esomeprazole) to GSL. Two pack sizes are available: 7s (£6.99) and 14s (£11.99). Indicated for short-term management of reflux symptoms (heartburn, acid regurgitation) in adults aged 18 years or over, the OTC treatment is recommended for a maximum of 14 consecutive days.

Heartburn sufferers are advised to contact a healthcare professional should symptoms persist. Pfizer says there are clear instructions in the patient leaflet and on the packaging to aid patients in identifying signs and symptoms for which they should seek advice from a healthcare professional.

“Pfizer welcomes the news that the MHRA has reclassified Nexium Control as an OTC treatment for heartburn,” says medical director Dr Toby Shephard. “We hope by allowing frequent heartburn sufferers greater access to this clinicallyeffective PPI treatment, it will help more people take better control of their symptoms GSL status for Nexium Control LloydsPharmacy has opened a clinic in an A&E department without the need to see a GP unless symptoms persist.”

The launch campaign, which starts this month, is supported by a consumer website (nexiumcontrol.co.uk).